In vitro loss-of-function and gain-of-function experiments combined with xenograft studies demonstrate that SIK2 attenuates proliferation and survival responses of breast cancer cells with concomitant inhibition of Ras/Erk and PI3K/Akt pathways. Here, AKT1 is linked to breast carcinoma.